The trypanosomiases

Lancet

Volumn 362, Issue 9394, 2003, Pages 1469-1480

  Barrett, Michael P ^a   Burchmore, Richard J S ^a   Stich, August ^b   Lazzari, Julio O ^c   Frasch, Alberto Carlos ^d   Cazzulo, Juan José ^d   Krishna, Sanjeev ^e  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Medical Mission Institute   (Germany)

^c Hospital Pirovano   (Argentina)

^d INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2,4 DIFLUOROPHENYL) 1 [3 [2 [4 (2,2,3,3 TETRAFLUOROPROPOXY)PHENYL]VINYL] 1,2,4 TRIAZOL 1 YL] 3 (1,2,4 TRIAZOL 1 YL) 2 PROPANOL; 2,5 BIS(4 AMIDINOPHENYL)FURAN BIS(DEXTRO METHYLAMIDOXIMINE); ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTITRYPANOSOMAL AGENT; BENZNIDAZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CYSTEINE PROTEINASE INHIBITOR; DB 289; DIAMIDINE DERIVATIVE; DIGITALIS; DIMINAZENE; DIMINAZENE ACETURATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFLORNITHINE; KETOCONAZOLE; LACTACYSTIN; MELARSOPROL; NIFURTIMOX; NITROIMIDAZOLE; ORGANOARSENIC DERIVATIVE; PENTAMIDINE; PENTOSE PHOSPHATE; POSACONAZOLE; PROTEASOME INHIBITOR; SURAMIN; TERBINAFINE; THIOL; THIOLACTOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AFRICAN TRYPANOSOMIASIS; ANTIBIOTIC RESISTANCE; ARTHROPOD; BRAIN DISEASE; CALORIC INTAKE; CELL DIFFERENTIATION; CELL INVASION; CHAGAS DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE CARRIER; DISEASE COURSE; DISEASE SEVERITY; DISEASE TRANSMISSION; DRUG DESIGN; DRUG MANUFACTURE; DRUG MECHANISM; DRUG TARGETING; EPIDEMIOLOGICAL DATA; EVOLUTION; FINANCIAL MANAGEMENT; GENE EXPRESSION REGULATION; GEOGRAPHIC DISTRIBUTION; GLUCOSE METABOLISM; HISTOPATHOLOGY; HOST PARASITE INTERACTION; HUMAN; INFECTION CONTROL; INSECT CONTROL; KINETOPLAST; LIPID METABOLISM; MORTALITY; NONHUMAN; NUTRIENT SUPPLY; POLYAMINE METABOLISM; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTOZOON; RNA EDITING; SIDE EFFECT; SIGNAL TRANSDUCTION; SODIUM RESTRICTION; STEROL METABOLISM; TREATMENT FAILURE; TREATMENT OUTCOME; TRYPANOSOMA BRUCEI; TRYPANOSOMA CRUZI;

EID: 0242298279     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(03)14694-6     Document Type: Conference Paper

References (125)

1. The World Health Report, 2002. 2002;World Health Organization, Geneva.
2. Burri C., Brun R. Human African trypanosomiasis. Cook G.C., Zumla A. Manson's tropical disease. 21st edn: 2003;1303-1323 Elsevier Science, London.
3. Miles M. American trypanosomiasis (Chagas disease). Cook G.C., Zumla A. Manson's tropical disease. 21st edn: 2003;1325-1337 Elsevier Science, London.
4. Herwaldt B.L. Leishmaniasis. Lancet. 354:1999;1191-1199.
5. Stevens J.R., Noyes H.A., Schofield C.J., Gibson W. The molecular evolution of Trypanosomatidae. Adv Parasitol. 48:2001;1-56.
6. Stevens J.R., Noyes H.A., Dover G.A., Gibson W.C. The ancient and divergent origins of the human pathogenic trypanosomes, Trypanosoma brucei and T cruzi. Parasitology. 118:1999;107-116.
7. Guhl F., Jaramillo C., Vallejo G.A., Cardenas A.-Arroyo F., Aufderheide A. Chagas disease and human migration. Mem Inst Oswaldo Cruz. 95:2000;553-555.
8. Prata A. Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis. 1:2001;92-100.
9. Pepin J., Meda H.A. The epidemiology and control of human African trypanosomiasis. Adv Parasitol. 49:2001;71-132.
10. MacLeod A., Tait A., Turner C.M.R. The population genetics of Trypanosoma brucei and the origin of human infectivity. Philos Trans R Soc Lond B Biol Sci. 356:2001;1035-1044.
11. MacLeod A., Tweedie A., Welburn S.C., Maudlin I., Turner C.M.R., Tait A. Minisatellite marker analysis of Trypanosoma brucei: reconciliation of clonal, panmictic, and epidemic population genetic structures. Proc Natl Acad Sci USA. 7:2000;13442-13447.
12. Gibson W. Epidemiology and diagnosis of African trypanosomiasis using DNA probes. Trans R Soc Trop Med Hyg. 96:(suppl 1):2002;S141-S143.
13. Raper J., Portela M.P., Lugli E., Frevert U., Tomlinson S. Trypanosome lytic factors: novel mediators of human innate immunity. Curr Opin Microbiol. 4:2001;402-408.
14. Raper J., Portela Molina M.P., Redpath M., Tomlinson S., Lugli E., Green H. Natural immunity to human African trypanosomiasis: trypanosome lytic factors and the blood incubation infectivity test. Trans R Soc Trop Med Hyg. 96:(suppl 1):2002;S145-S150.
15. Hager K.M., Hajduk S.L. Mechanism of resistance of African trypanosomes to cytotoxic human HDL. Nature. 385:1997;823-826.
16. Vanhamme L., Paturiaux-Hanocq F., Poelvoorde P., et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature. 422:2003;83-87.
17. De Greef C., Imberechts H., Matthyssens G., Van Meirvenne N., Hamers R. A gene expressed only in serum-resistant variants of Trypanosoma brucei rhodesiense. Mol Biochem Parasitol. 36:1989;169-176.
18. Xong H.V., Vanhamme L., Chamekh M., et al. A VSG expression site-associated gene confers resistance to human serum in Trypanosoma rhodesiense. Cell. 95:1998;839-846.
19. Welburn S.C., Picozzi K., Fevre E.M., et al. Identification of human-infective trypanosomes in animal reservoir of sleeping sickness in Uganda by means of serum-resistance-associated (SRA) gene. Lancet. 358:2001;2017-2019.
20. Cattand P., Jannin J., Lucas P. Sleeping sickness surveillance: an essential step towards elimination. Trop Med Int Health. 6:2001;348-361.
21. Remme J.H., Blas E., Chitsulo L., et al. Strategic emphases for tropical diseases research: a TDR perspective. Trends Parasitol. 18:2002;421-426.
22. Pays J.F. American human trypanosomiasis 90 years after its discovery by Carlos Chagas, I: epidemiology and control. Med Trop (Mars). 58:1998;391-402.
23. Fernandes O., Souto R.P., Castro J.A., et al. Brazilian isolates of Trypanosoma cruzi from humans and triatomines classified into two lineages using mini-exon and ribosomal RNA sequences. Am J Trop Med Hyg. 58:1998;807-811.
24. Laurent J.P., Barnabe C., Quesney V., Noel S., Tibayrenc M. Impact of clonal evolution on the biological diversity of Trypanosoma cruzi. Parasitology. 114:1997;213-218.
25. Gaunt M.W., Yeo M., Frame I.A., et al. Mechanism of genetic exchange in American trypanosomes. Nature. 421:2003;936-939.
26. Borst P., Fairlamb A.H. Surface receptors and transporters of Trypanosoma brucei. Annu Rev Microbiol. 52:1998;745-778.
27. Barry J.D., McCulloch R. Antigenic variation in trypanosomes: enhanced phenotypic variation in a eukaryotic parasite. Adv Parasitol. 49:2001;1-70.
28. Borst P. Antigenic variation and allelic exclusion. Cell. 109:2002;5-8.
29. Reina-San-Martin B., Degrave W., Rougeot C., et al. A B-cell mitogen from a pathogenic trypanosome is a eukaryotic proline racemase. Nat Med. 6:2000;890-897.
30. Frasch A.C. Functional diversity in the trans-sialidase and mucin families in Trypanosoma cruzi. Parasitol Today. 16:2000;282-286.
31. Acosta-Serrano A., Almeida I.C., Freitas-Junior L.H., Yoshida N., Schenkman S. The mucin-like glycoprotein super-family of Trypanosoma cruzi: structure and biological roles. Mol Biochem Parasitol. 114:2001;143-150.
32. Pollevick G.D., Di Noia J.M., Salto M.L., et al. Trypanosoma cruzi surface mucins with exposed variant epitopes. J Biol Chem. 275:2000;27671-27680.
33. Almeida I.C., Camargo M.M., Procopio D.O., et al. Highly purified glycosylphosphatidylinositols from Trypanosoma cruzi are potent proinflammatory agents. EMBO J. 19:2000;1476-1485.
34. Magez S., Stijlemans B., Radwanska M., Pays E., Ferguson M.A., De Baetselier P. The glycosyl-inositol-phosphate and dimyristoylglycerol moieties of the glycosylphosphatidylinositol anchor of the trypanosome variant-specific surface glycoprotein are distinct macrophage-activating factors. J Immunol. 160:1998;1949-1956.
35. Nyakundi J.N., Crawley B., Smith R.A., Pentreath V.W. The relationships between intestinal damage and circulating endotoxins in experimental Trypanosoma brucei brucei infections. Parasitology. 124:2002;589-595.
36. Stich A., Abel P.M., Krishna S. Human African trypanosomiasis. BMJ. 325:2002;203-206.
37. Stich A. Trypanosomiases. Medicine. 29:2001;42-45.
38. Dumas M., Bisser S. Clinical aspects of human African trypanosomiasis. Dumas M., Bouteille B., Buguet A. Progress in human African trypanosomiasis, sleeping sickness. 1998;215-233 Springer, Paris.
39. Control and surveillance of African trypanosomiasis: report of a WHO Expert Committee (WHO technical report series, no 881). 1998;World Health Organization, Geneva.
40. Louis F.J., Buscher P., Lejon V. Diagnosis of human African trypanosomiasis in 2001. Med Trop (Mars). 61:2001;340-346.
41. Penchenier L., Simo G., Grebaut P., Nkinin S., Laveissiere C., Herder S. Diagnosis of human trypanosomiasis, due to Trypanosoma brucei gambiense in central Africa, by the polymerase chain reaction. Trans R Soc Trop Med Hyg. 94:2000;392-394.
42. Enanga B., Burchmore R.J., Stewart M.L., Barrett M.P. Sleeping sickness and the brain. Cell Mol Life Sci. 59:2002;845-858.
43. Pentreath V.W. Trypanosomiasis and the nervous system: pathology and immunology. Trans R Soc Trop Med Hyg. 89:1995;9-15.
44. Poltera A.A. Pathology of human African trypanosomiasis with reference to experimental African trypanosomiasis and infections of the central nervous system. Br Med Bull. 41:1985;169-174.
45. Chimelli L., Scaravilli F. Trypanosomiasis. Brain Pathol. 7:1997;599-611.
46. Buguet A., Bourdon L., Bouteille B., et al. The duality of sleeping sickness: focusing on sleep. Sleep Med Rev. 5:2001;139-153.
47. Jauberteau M.O., Younes-Chennoufi A.B., Amevigbe M., et al. Galactocerebrosides are antigens for immunoglobulins in sera of an experimental model of trypanosomiasis in sheep. J Neurol Sci. 101:1991;82-86.
48. Rassi A. Jr, Rassi A., Little W.C. Chagas heart disease. Clin Cardiol. 23:2000;883-889.
49. Girones N., Fresno M. Etiology of Chagas disease myocarditis: autoimmunity, parasite persistence, or both? Trends Parasitol. 19:2003;19-22.
50. Engman D.M., Leon J.S. Pathogenesis of Chagas heart disease: role of autoimmunity. Acta Trop. 81:2002;123-132.
51. Soares M.B., Pontes-De-Carvalho L., Ribeiro-Dos-Santos R. The pathogenesis of Chagas disease: when autoimmune and parasite-specific immune responses meet. An Acad Bras Cienc. 73:2001;547-559.
52. Leon J.S., Engman D.M. Autoimmunity in Chagas heart disease. Int J Parasitol. 31:2001;555-561.
53. Tarleton R.L. Parasite persistence in the aetiology of Chagas disease. Int J Parasitol. 31:2001;550-554.
54. Control of Chagas disease, 2nd report of the WHO expert committee on Chagas disease (WHO technical report series, no 905). 2002;World Health Organization, Geneva.
55. Marcon G.E., Andrade P.D., de Albuquerque D.M., et al. Use of a nested polymerase chain reaction (N-PCR) to detect Trypanosoma cruzi in blood samples from chronic chagasic patients and patients with doubtful serologies. Diagn Microbiol Infect Dis. 43:2002;39-43.
56. Pepin J., Milord F. The treatment of human African trypanosomiasis. Adv Parasitol. 33:1994;1-47.
57. Keiser J., Stich A., Burri C. New drugs for the treatment of human African trypanosomiasis: research and development. Trends Parasitol. 17:2001;42-49.
58. Burchmore R.J., Ogbunude P.O., Enanga B., Barrett M.P. Chemotherapy of human African trypanosomiasis. Curr Pharm Des. 8:2002;256-267.
59. Legros D., Ollivier G., Gastellu-Etchegorry M., et al. Treatment of human African trypanosomiasis: present situation and needs for research and development. Lancet Infect Dis. 2:2002;437-440.
60. Urbina J.A. Chemotherapy of Chagas disease. Curr Pharm Des. 8:2002;287-295.
61. Urbina J.A. Specific treatment of Chagas disease: current status and new developments. Curr Opin Infect Dis. 14:2001;733-741.
62. Pepin J., Milord F. African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis. Trans R Soc Trop Med Hyg. 85:1991;222-224.
63. Burri C., Nkunku S., Merolle A., Smith T., Blum J., Brun R. Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial. Lancet. 355:2000;1419-1425.
64. Pepin J., Khonde N., Maiso F., et al. Short-course eflornithine in Gambian trypanosomiasis: a multicentre randomized controlled trial. Bull World Health Organ. 78:2000;1284-1295.
65. Jennings F.W. Combination chemotherapy of CNS trypanosomiasis. Acta Trop. 54:1993;205-213.
66. Jennings F.W., Rodgers J., Bradley B., Gettinby G., Kennedy P.G., Murray M. Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen. Parasitol Int. 51:2002;381-388.
67. Mpia B., Pepin J. Combination of eflornithine and melarsoprol for melarsoprol-resistant Gambian trypanosomiasis. Trop Med Int Health. 7:2002;775-779.
68. Legros D., Evans S., Maiso F., Enyaru J.C., Mbulamberi D. Risk factors for treatment failure after melarsoprol for Trypanosoma brucei gambiense trypanosomiasis in Uganda. Trans R Soc Trop Med Hyg. 93:1999;439-442.
69. Brun R., Schumacher R., Schmid C., Kunz C., Burri C. The phenomenon of treatment failures in human African trypanosomiasis. Trop Med Int Health. 6:2001;906-914.
70. Barrett M.P., Fairlamb A.H. The biochemical basis of arsenical-diamidine crossresistance in African trypanosomes. Parasitol Today. 15:1999;136-140.
71. Trouiller P., Olliaro P., Torreele E., Orbinski J., Laing R., Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 359:2002;2188-2194.
72. Trouiller P., Battistella C., Pinel J., Pecoul B. Is orphan drug status beneficial to tropical disease control? Comparison of the American and future European orphan drug acts. Trop Med Int Health. 4:1999;412-420.
73. Etchegorry M.G., Helenport J.P., Pecoul B., Jannin J., Legros D. Availability and affordability of treatment for human African trypanosomiasis. Trop Med Int Health. 6:2001;957-959.
74. Stich A., Barrett M.P., Krishna S. Waking up to sleeping sickness. Trends Parasitol. 19:2003;195-197.
75. Médecins Sans Frontières. Drugs for neglected diseases initiative. http://www.accessmed-msf.org/dnd/dndi.asp (accessed Aug 26, 2003).
76. de Andrade A.L., Ziker F., de Oliveira R.M., et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet. 348:1996;1407-1414.
77. Sosa Estani S., Segura E.L., Ruiz A.M., Velazquez E., Porcel B.M., Yampotis C. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas disease. Am J Trop Med Hyg. 59:1998;526-529.
78. Da Silva A.L. Chagas disease surgery. Mem Inst Oswaldo Cruz. 94:(suppl 1):1999;343-347.
79. Wang C.C. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu Rev Pharmacol Toxicol. 35:1995;93-127.
80. Croft S.L. Pharmacological approaches to antitrypanosomal chemotherapy. Mem Inst Oswaldo Cruz. 94:1999;215-220.
81. Degrave W.M., Melville S., Ivens A., Aslett M. Parasite genome initiatives. Int J Parasitol. 31:2001;532-536.
82. Kelly J.M., Taylor M.C., Rudenko G., Blundell P.A. Transfection of the African and American trypanosomes. Methods Mol Biol. 47:1995;349-359.
83. Clayton C.E. Genetic manipulation of kinetoplastida. Parasitol Today. 15:1999;72-78.
84. LaCount D.J., Donelson J.E. RNA interference in African trypanosomes. Protist. 152:2001;103-111.
85. Michels P.A., Hannaert V., Bringaud F. Metabolic aspects of glycosomes in trypanosomatidae: new data and views. Parasitol Today. 16:2000;482-489.
86. Cazzulo J.J. Intermediate metabolism in Trypanosoma cruzi. J Bioenerg Biomemb. 26:1994;157-165.
87. Verlinde C.L., Hannaert V., Blonski C., et al. Glycolysis as a target for the design of new anti-trypanosome drugs. Drug Resist Updat. 4:2001;50-65.
88. Lakhdar-Ghazal F., Blonski C., Willson M., Michels P., Perie J. Glycolysis and proteases as targets for the design of new anti-trypanosome drugs. Curr Top Med Chem. 2:2002;439-456.
89. Aronov A.M., Suresh S., Buckner F.S., et al. Structure-based design of submicromolar, biologically active inhibitors of trypanosomatid glyceraldehyde-3-phosphate dehydrogenase. Proc Natl Acad Sci USA. 96:1999;4273-4278.
90. Barrett M.P. The pentose phosphate pathway and parasitic protozoa. Parasitol Today. 13:1997;11-16.
91. Hannaert V., Saavedra E., Duffieux F., et al. Plant-like traits associated with metabolism of Trypanosoma parasites. Proc Natl Acad Sci USA. 100:2003;1067-1071.
92. Barrett M.P., Gilbert I.H. Perspectives for new drugs against trypanosomiasis and leishmaniasis. Curr Top Med Chem. 2:2002;471-482.
93. Fairlamb A.H., Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu Rev Microbiol. 46:1992;695-729.
94. Schmidt A., Krauth-Siegel R.L. Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development. Curr Top Med Chem. 2:2002;1239-1259.
95. Bacchi C.J., Nathan H.C., Hutner S.H., McCann P.P., Sjoerdsma A. Polyamine metabolism: a potential therapeutic target in trypanosomes. Science. 210:1980;332-334.
96. Muller S., Coombs G.H., Walter R.D. Targeting polyamines of parasitic protozoa in chemotherapy. Trends Parasitol. 17:2001;242-249.
97. Le Quesne S.A., Fairlamb A.H. Regulation of a high-affinity diamine transport system in Trypanosoma cruzi epimastigotes. Biochem J. 316:1996;481-486.
98. Urbina J.A. Lipid biosynthesis pathways as chemotherapeutic targets in kinetoplastid parasites. Parasitology. 114:(suppl):1997;S91-S99.
99. Docampo R. Recent developments in the chemotherapy of Chagas disease. Curr Pharmaceut Design. 7:2001;1157-1164.
100. Paul K.S., Jiang D., Morita Y.S., Englund P.T. Fatty acid synthesis in African trypanosomes: a solution to the myristate mystery. Trends Parasitol. 17:2001;381-387.
101. Buckner F.S., Yokoyama K., Nguyen L., et al. Cloning, heterologous expression, and distinct substrate specificity of protein farnesyltransferase from Trypanosoma brucei. J Biol Chem. 275:2000;21870-21876.
102. Ali B.R., Pal A., Croft S.L., Taylor R.J., Field M.C. The farnesyltransferase inhibitor manumycin A is a novel trypanocide with a complex mode of action including major effects on mitochondria. Mol Biochem Parasitol. 104:1999;67-80.
103. Troeberg L., Morty R.E., Pike R.N., et al. Cysteine proteinase inhibitors kill cultured bloodstream forms of Trypanosoma brucei brucei. Exp Parasitol. 91:1999;349-355.
104. Cazzulo J.J. Proteinases of Trypanosoma cruzi: potential targets for the chemotherapy of Chagas desease. Curr Top Med Chem. 2:2002;1261-1271.
105. Caffrey C.R., Scory S., Steverding D. Cysteine proteinases of trypanosome parasites: novel targets for chemotherapy. Curr Drug Targets. 1:2000;155-162.
106. Whitby F.G., Masters E.I., Kramer L., et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature. 408:2000;115-120.
107. Hasne M., Barrett M.P. Drug uptake via nutrient transporters in Trypanosoma brucei. J Appl Microbiol. 89:2000;697-701.
108. Ferguson M.A., Brimacombe J.S., Brown J.R., et al. The GPI biosynthetic pathway as a therapeutic target for African sleeping sickness. Biochim Biophys Acta. 1455:1999;327-340.
109. Shapiro T.A., Englund P.T. The structure and replication of kinetoplast DNA. Annu Rev Microbiol. 49:1995;117-143.
110. Stuart K., Allen T.E., Heidmann S., Seiwert S.D. RNA editing in kinetoplastid protozoa. Microbiol Mol Biol Rev. 61:1997;105-120.
111. Schnaufer A., Domingo G.J., Stuart K. Natural and induced dyskinetoplastic trypanosomatids: how to live without mitochondrial DNA. Int J Parasitol. 32:2002;1071-1084.
112. Vanhamme L., Pays E. Control of gene expression in trypanosomes. Microbiol Rev. 59:1995;223-240.
113. Docampo R., Moreno S.N. The acidocalcisome. Mol Biochem Parasitol. 114:2001;151-159.
114. Rahmathullah S.M., Hall J.E., Bender B.C., McCurdy D.R., Tidwell R.R., Boykin D.W. Prodrugs for amidines: synthesis and anti-Pneumocystis carinii activity of carbamates of 2,5-bis(4-amidinophenyl)furan. J Med Chem. 42:1999;3994-4000.
115. Rodriques Coura J., de Castro S.L. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz. 97:2002;3-24.
116. Schofield C.J., Maudlin I. Trypanosomiasis control. Int J Parasitol. 31:2001;614-619.
117. Dias J.C., Silveira A.C., Schofield C.J. The impact of Chagas disease control in Latin America: a review. Mem Inst Oswaldo Cruz. 97:2002;603-612.
118. Schofield C.J., Dias J.C. The Southern Cone Initiative against Chagas disease. Adv Parasitol. 42:1999;1-27.
119. Allsopp R. Options for vector control against trypanosomiasis in Africa. Trends Parasitol. 17:2001;15-19.
120. Jannin J., Louis F.J., Lucas P., Simarro P.P. Control of human African trypanosomiasis: back to square one. Med Trop (Mars). 61:2001;437-440.
121. Grant I.F. Insecticides for tsetse and trypanosomiasis control: is the environmental risk acceptable? Trends Parasitol. 17:2001;10-14.
122. Hargrove J.W., Omolo S., Msalilwa J.S., Fox B. Insecticide-treated cattle for tsetse control: the power and the problems. Med Vet Entomol. 14:2000;123-130.
123. Vreysen M.J. Principles of area-wide integrated tsetse fly control using the sterile insect technique. Med Trop (Mars). 61:2001;397-411.
124. Glasgow J.P., Potts W.H. Control by hand-catching and traps. Mulligan H.W. The African trypanosomiases. 1970;456-463 George Allen and Unwin, London.
125. Rogers D.J., Randolph S.E. A response to the aim of eradicating tsetse from Africa. Trends Parasitol. 18:2002;534-536.